# ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

> **NCT00294437** · PHASE3 · TERMINATED · sponsor: **Central European Cooperative Oncology Group** · enrollment: 376 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Zometa

## Key facts

- **NCT ID:** NCT00294437
- **Lead sponsor:** Central European Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** 2003-12
- **Final completion:** 2007-11
- **Target enrollment:** 376 (ACTUAL)
- **Why stopped:** underfunding
- **Last updated:** 2012-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00294437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00294437, "ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00294437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*